Clinical trials are essential to evaluating the safety and efficacy of new therapies for patients living with immunologic conditions. Availability of data from clinical trials sponsored by UCB provides transparency and fosters advances in patient care. As part of our commitment to patients and the healthcare community at large, UCB shares information about our clinical trials and makes the results of these studies publicly available. The interventions being studied and their uses may be investigational and not approved by the US Food and Drug Administration. Note: Searching by the generic name (e.g., certolizumab pegol) may deliver different results than a search by the code name (e.g., CDP870); therefore, it may be necessary to search by both for complete results.
If you are interested in being an investigator for a UCB-sponsored clinical trial, please forward your curriculum vitae, including a brief description of your therapeutic area specialty, along with the NCT number of the study you are interested in (if applicable) to:
UCBCOMPASS® offers links to third party websites provided solely for your convenience that may assist you in locating other useful information. UCB is not responsible for content or privacy policies on linked third-party websites that are not under the control of UCB.
Do you wish to continue?
Please enter the email address associated with your UCBCOMPASS® account.
Password reset instructions will be mailed to your registered email address.
If you no longer use the email associated with your account, please contact firstname.lastname@example.org for further support.
UCBCOMPASS® provides accurate, unbiased, and non-promotional scientific education and medical information on UCB products and disease areas of focus. This content is for informational purposes only and is not intended as medical advice. It may include information about products or uses that have not been approved by the U.S. Food and Drug Administration.
Any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which may or may not have a causal relationship with this treatment.
Additional safety information includes (but is not limited to) the following report types: